Asenapine

Active ingredient: Asenapine

In short: Asenapine is indicated for: Schizophrenia in adults Bipolar I disorder Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age Adjunctive treatment to lithium or valproate in adults Maintenance monotherapy treatment in adults

Forms & strengths2.5 mg: White to off white, round tablets debossed with ‘L’ on one side and ‘70’ on the other side. 5 mg: White to off white, round tablets debossed with “464” on one side and plain on other side. …
LabelAlembic Pharmaceuticals Limited
Label updatedOct 28, 2026

What is Asenapine used for?

Asenapine is indicated for:

Schizophrenia in adults

Bipolar I disorder

Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age

Adjunctive treatment to lithium or valproate in adults

Maintenance monotherapy treatment in adults

⚠ Boxed warning (FDA's strongest warning)

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Asenapine is not approved for the treatment of patients with dementia-related psychosis

.

Asenapine dosage

Asenapine is a sublingual tablet. To ensure optimal absorption, patients should be instructed to place the tablet under the tongue and allow it to dissolve completely. The tablet will dissolve in saliva within seconds. Asenapine sublingual tablets should not be split, crushed, chewed, or swallowed . Patients should be instructed to not eat or drink for 10 minutes after administration .

The recommended dose of asenapine is 5 mg given twice daily. In short-term controlled trials, there was no suggestion of added benefit with a 10 mg twice daily dose, but there was a clear increase in certain adverse reactions. If tolerated, daily dosage can be increased to 10 mg twice daily after one week. The safety of doses above 10 mg twice daily has not been evaluated in clinical studies .

Acute Treatment of Manic or Mixed Episodes:

Monotherapy in Adults:

The recommended starting and treatment dose of asenapine is 5 mg to 10 mg twice daily. The safety of doses above 10 mg twice daily has not been evaluated in clinical trials .

Monotherapy in Pediatric Patients:

The recommended dose of asenapine is 2.5 mg to 10 mg twice daily in pediatric patients 10 to 17 years of age, and dose may be adjusted for individual response and tolerability. The starting dose of asenapine is 2.5 mg twice daily. After 3 days, the dose can be increased to 5 mg twice daily, and from 5 mg to 10 mg twice daily after 3 additional days. Pediatric patients aged 10 to 17 years appear to be more sensitive to dystonia with initial dosing with asenapine when the recommended escalation schedule is not followed . The safety of doses greater than 10 mg twice daily has not been evaluated in clinical trials .

Adjunctive Therapy in Adults:

The recommended starting dose of asenapine is 5 mg twice daily when administered as adjunctive therapy with either lithium or valproate. Depending on the clinical response and tolerability in the individual patient, the dose can be increased to 10 mg twice daily. The safety of doses above 10 mg twice daily as adjunctive therapy with lithium or valproate has not been evaluated in clinical trials.

For patients on asenapine, whether used as monotherapy or as adjunctive therapy with lithium or valproate, it is generally recommended that responding patients continue treatment beyond the acute episode.

Maintenance Treatment of Bipolar I Disorder:

Monotherapy in Adults: Continue on the asenapine dose that the patient received during stabilization (5 mg to 10 mg twice daily). Depending on the clinical response and tolerability in the individual patient, a dose of 10 mg twice daily can be decreased to 5 mg twice daily. The safety of doses above 10 mg twice daily has not been evaluated in clinical trials .

How to take Asenapine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Instructions for Use).

Dosage and Administration

Counsel patients on proper sublingual administration of asenapine and advise them to read the FDA-approved patient labeling (Instructions for Use). When initiating treatment with asenapine, provide dosage escalation instructions .

Hypersensitivity Reactions

Counsel patients on the signs and symptoms of a serious allergic reaction (e.g., difficulty breathing, itching, swelling of the face, tongue or throat, feeling lightheaded etc.) and to seek immediate emergency assistance if they develop any of these signs and symptoms .

Application Site Reactions

Inform patients that application site reactions, primarily in the sublingual area, including oral ulcers, blisters, peeling/sloughing and inflammation have been reported. Instruct patients to monitor for these reactions . Inform patients that numbness or tingling of the mouth or throat may occur directly after administration of asenapine and usually resolves within 1 hour . …

Warnings & precautions

Do not take this medicine if: Asenapine is contraindicated in patients with:

Severe hepatic impairment (Child-Pugh C) .

A history of hypersensitivity reactions to asenapine. Reactions have included anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash .

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Asenapine is not approved for the treatment of patients with dementia-related psychosis .

In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. Asenapine is not approved for the treatment of patients with dementia-related psychosis .

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, delirium, and autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. …

Asenapine side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Use in Elderly Patients with Dementia-Related Psychosis

Neuroleptic Malignant Syndrome

Tardive Dyskinesia

Metabolic Changes

Hypersensitivity Reactions

Orthostatic Hypotension, Syncope, and other Hemodynamic Effects

Falls

Leukopenia, Neutropenia, and Agranulocytosis

QT Interval Prolongation

Hyperprolactinemia

Seizures

Potential for Cognitive and Motor Impairment

Body Temperature Regulation

Dysphagia

The most common adverse reactions (≥5% and at least twice the rate of placebo) reported with acute treatment in adults with schizophrenia were akathisia, oral hypoesthesia, and somnolence. The safety profile of asenapine in the maintenance treatment of schizophrenia in adults was similar to that seen with acute treatment.

The most common adverse reactions (≥5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, oral hypoesthesia dizziness, extrapyramidal symptoms (excluding akathisia) and akathisia; and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia. The rates were lower at the 5 mg twice daily dose than the 10 mg twice daily dose for all of these most common adverse reactions. …

Drug interactions

Table 12: Clinically Important Drug Interactions with Asenapine

Concomitant Drug Name or Drug Class | Clinical Rationale | Clinical Recommendation

Antihypertensive Drugs | Because of its α1-adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents . | Monitor blood pressure and adjust dosage of antihypertensive drug accordingly.

Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) | Asenapine is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when asenapine is used with fluvoxamine at 25 mg administered twice daily . However, the tested fluvoxamine dose was suboptimal. Full therapeutic dose of fluvoxamine is expected to cause a greater increase in asenapine exposure. | Dosage reduction for asenapine based on clinical response may be necessary.

CYP2D6 substrates and inhibitors (e.g., paroxetine) | Asenapine may enhance the inhibitory effects of paroxetine on its own metabolism. Concomitant use of paroxetine with asenapine increased the paroxetine exposure by 2-fold as compared to use paroxetine alone . | Reduce paroxetine dose by half when paroxetine is used in combination with asenapine. …

About this medicine

Asenapine sublingual tablet contains asenapine maleate which is an atypical antipsychotic that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-2 butenedioate (1:1). Its molecular formula is C17H16ClNO⋅C4H4O4 and its molecular weight is 401.84 (free base: 285.8). The chemical structure is:

Asenapine maleateis off-white to white powder.

Asenapine is supplied for sublingual administration in tablets containing 2.5-mg, 5-mg or 10-mg asenapine; inactive ingredients include butylated hydroxyanisole, butylated hydroxytoluene, low-substituted hydroxypropyl cellulose, mannitol, povidone, sodium stearyl fumarate.

How it works: The mechanism of action of asenapine in schizophrenia and bipolar I disorder is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D2 and 5HT2A receptors. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cf587c48-9cd2-4dc5-b0e9-21783c5633a6. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone